Mycoplasma in Poultry: A Veterinary Clinical Guide to Diagnosis and Management

1. Introduction and Etiology

Avian mycoplasmosis represents a group of economically significant infectious diseases of poultry caused by bacteria belonging to the genus Mycoplasma [1]. These organisms are characterized by their small genome size, lack of a cell wall, and dependence on a cholesterol-rich environment for growth [2]. Among the more than 20 Mycoplasma species identified in avian hosts, Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) are recognized as the most clinically and economically important pathogens for commercial chicken and turkey production worldwide [3, 1]. Mycoplasma gallisepticum is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [1, 2]. Mycoplasma synoviae causes synovitis, airsacculitis, and subclinical respiratory infections, and can also contribute to eggshell apex abnormalities in laying hens [1, 4]. Other pathogenic species include Mycoplasma meleagridis (MM) and Mycoplasma iowae (MI), which primarily affect turkeys [1]. The global distribution of these pathogens is well documented, with prevalence studies demonstrating their presence across diverse geographic regions including Europe, Asia, Africa, and the Americas [5, 6, 7, 8].

2. Pathogenesis and Host-Pathogen Interactions

The pathogenesis of MG and MS infection begins with colonization of the respiratory mucosa. Mycoplasma gallisepticum possesses specialized tip organelles that mediate adhesion to ciliated epithelial cells of the trachea, nasal passages, and air sacs [9, 2]. This adhesion is mediated by cytadhesin proteins, including the mgc2 gene product, which is a critical virulence factor [10, 11]. Following attachment, the organism induces ciliostasis, deciliation, and a pronounced inflammatory response characterized by lymphocytic and plasmacytic infiltration of the submucosa [12, 9]. The resulting tracheal mucosal thickening, measured as tracheal mucosal thickness (TMT), is a key pathological parameter used to assess disease severity and vaccine efficacy [12]. The inflammatory response leads to exudate accumulation, air sac opacity, and the classic clinical signs of respiratory distress [9].

Mycoplasma synoviae infection is initiated via the respiratory route, with subsequent hematogenous dissemination to synovial membranes, particularly the hock and stifle joints [4]. The vlhA gene, encoding a hemagglutinin protein, is a major antigenic determinant and is subject to phase variation, allowing the organism to evade host immune responses [13, 4]. Co-infection with other respiratory pathogens, such as Escherichia coli, infectious bronchitis virus (IBV), or Avibacterium paragallinarum, significantly exacerbates disease severity through synergistic interactions [14, 15, 16]. The presence of MG can potentiate the pathogenicity of IBV, leading to more severe respiratory disease and increased mortality [16, 17].

3. Clinical Signs and Disease Manifestations

The clinical presentation of MG and MS infection varies with host species, age, immune status, and the presence of concurrent infections [1, 6].

Mycoplasma gallisepticum (MG):

• Chickens (CRD): Nasal discharge, rales, coughing, dyspnea, and depression [9, 2]. Infraorbital sinus swelling is common [18]. In laying flocks, there is a characteristic drop in egg production (5-20%), reduced feed conversion efficiency, and increased embryo mortality [1, 7].
• Turkeys (Infectious Sinusitis): Severe swelling of the infraorbital sinuses, nasal discharge, and respiratory distress [1].
• Subclinical Infection: Many flocks remain asymptomatic, with disease only manifesting under stress or during concurrent viral infections [5, 6].

Mycoplasma synoviae (MS):

• Respiratory Form: Mild rales, coughing, and airsacculitis, often subclinical [4].
• Synovial Form: Lameness, joint swelling (particularly hock joints), breast blisters, and reluctance to move [4].
• Eggshell Abnormalities: A characteristic thinning of the eggshell at the apex (eggshell apex abnormality) is associated with MS infection in some layer flocks [3].

4. Diagnostic Approaches

Accurate diagnosis of MG and MS infection is essential for implementing effective control programs. A combination of serological and molecular methods is recommended to maximize sensitivity and specificity [19, 10].

4.1 Serological Testing

Serological assays detect antibodies against MG and MS, but cannot distinguish between active infection and vaccine-induced immunity [19].

• Rapid Serum Agglutination (RSA) Test: A simple, inexpensive, and rapid test using stained antigen. It is performed at a 1:10 dilution on serum. However, it has lower sensitivity and specificity compared to other methods, with a higher risk of false positives from non-specific agglutinins [19]. Reported positivity rates for MG range from 14.8% to 28.5% in some studies [19].
• Hemagglutination Inhibition (HI) Assay: A more specific test that measures antibodies capable of inhibiting hemagglutination by MG. It is considered the gold standard for serotyping but is more labor-intensive [19]. Positivity rates for MG are typically lower than RSA (e.g., 8.7%) [19].
• Enzyme-Linked Immunosorbent Assay (ELISA): Commercial ELISA kits are widely used for high-throughput screening. They offer high sensitivity and specificity, and can be used to quantify antibody levels [19, 18]. In-house ELISA kits using whole or sonicated MG antigens have shown high correlation with commercial kits [18]. Seroprevalence rates for MG in commercial layers can exceed 70% in some regions [6, 20].

4.2 Molecular Detection

Polymerase chain reaction (PCR) based assays provide direct detection of Mycoplasma DNA, offering higher sensitivity and specificity than culture, and are not affected by vaccination status [19, 21, 10].

• Conventional PCR (cPCR): Targets specific genes such as the 16S rRNA gene, the mgc2 gene (for MG), or the vlhA gene (for MS) [13, 11, 4]. It provides a qualitative result (positive/negative) and is suitable for routine surveillance [19].
• Real-Time PCR (qPCR): Offers quantitative detection (quantifying DNA load) and is more sensitive than cPCR. It can detect MG and MS directly from tracheal swabs with high accuracy [21, 10, 5]. Duplex qPCR assays allow simultaneous detection of both MG and MS in a single reaction [5, 13].
• Nested PCR (nPCR): Increases sensitivity by using two rounds of amplification, but carries a higher risk of contamination [19].
• Vaccine Strain PCR: A specific PCR assay that can differentiate vaccine strains (e.g., MG-F strain) from field strains by targeting unique genetic sequences [19]. This is critical for interpreting positive results in vaccinated flocks.

4.3 Culture and Isolation

Conventional culture on modified Frey's media (PPLO broth) is the traditional gold standard but is slow (requiring 7-21 days), has low sensitivity (approximately 34.5%), and is technically demanding [10, 4]. It is primarily used for research and antimicrobial susceptibility testing [22, 23].

4.4 Diagnostic Workflow

The following Mermaid diagram illustrates a recommended diagnostic workflow for a poultry flock presenting with respiratory signs.

graph TD
    A[Flock with Respiratory Signs], > B{Clinical History & Physical Exam};
    B, > C[Collect Samples];
    C, > D[Tracheal Swabs (for PCR/Culture)];
    C, > E[Serum (for Serology)];
    C, > F[Trachea/Lungs (for PCR at Necropsy)];
    D, > G{Initial Screening: RSA Test};
    E, > G;
    G, > H{Positive?};
    H, Yes, > I[Confirm with HI or ELISA];
    H, No, > J[Consider Subclinical/Low Titer];
    I, > K{Confirmatory PCR (qPCR or cPCR)};
    J, > K;
    K, > L{Result};
    L, MG or MS Positive, > M[Identify as Field or Vaccine Strain];
    L, Negative, > N[Re-evaluate for Other Pathogens];
    M, > O[Antimicrobial Susceptibility Testing (if indicated)];
    O, > P[Implement Control & Treatment];
    N, > P;

5. Treatment and Antimicrobial Therapy

Treatment of MG and MS infections is primarily aimed at reducing clinical signs and economic losses, as complete eradication from a flock is rarely achievable [3, 1]. Antimicrobial therapy is the mainstay of treatment, but the emergence of resistance is a growing concern [24, 23].

• Tetracyclines: Doxycycline and oxytetracycline are commonly used and have demonstrated good in vitro activity against MG [23]. They are administered via feed or water.
• Macrolides: Tylosin, tilmicosin, and spiramycin are widely used for respiratory mycoplasmosis [23, 25]. However, high rates of resistance have been reported, with some studies showing 87.5% of isolates resistant to tilmicosin and 68.75% to tylosin [23].
• Fluoroquinolones: Enrofloxacin and difloxacin are effective but are associated with resistance development, particularly through mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC [24]. Substitutions such as Ser83 to Ile in gyrA and Ser80 to Leu in parC have been linked to increased minimum inhibitory concentrations (MICs) [24].
• Novel Antimicrobials: Spirulina platensis extract has shown in vitro antimicrobial activity against macrolide-resistant MG strains, with MICs ranging from 3.9 to 1,000 μg/mL, and a favorable safety profile (no cytotoxicity up to 4,000 μg/mL) [23]. Microemulsion formulations are also being investigated for their synergistic effects against multi-resistant MG [22].

6. Control and Prevention Strategies

Effective control of avian mycoplasmosis relies on a multi-faceted approach combining biosecurity, vaccination, and monitoring [3, 1].

6.1 Biosecurity

• Hygiene and Sanitation: Strict cleaning and disinfection protocols are critical, as Mycoplasma is susceptible to common disinfectants [26]. Farms with soil floors and uncoated walls are at higher risk [26].
• Isolation and Quarantine: New birds should be isolated for at least 30 days. All-in/all-out management is recommended [26].
• Wild Bird Control: Wild birds, particularly European starlings, can act as reservoirs for MG-like strains, posing a risk to commercial flocks [27]. Biosecurity measures should include preventing wild bird access [26].

6.2 Vaccination

• Live-Attenuated Vaccines: The MG-F strain, ts-11 strain, and 6/85 strain are commonly used as live vaccines [12, 19, 7]. They are administered via eye drop, spray, or drinking water. They reduce clinical signs and air sac lesions but do not prevent infection [12]. Tracheal mucosal thickness (TMT) is a more discriminative parameter than air sac lesion scores for evaluating vaccine efficacy [12].
• Inactivated (Bacterin) Vaccines: These are used in layers and breeders to boost antibody levels and reduce egg transmission [1].
• Recombinant Vaccines: Poxvirus-vectored vaccines expressing MG antigens are available [1].

6.3 Monitoring and Eradication

• Serological Surveillance: Regular testing (e.g., every 6-12 weeks) using ELISA or HI is essential to detect early infection [19, 28].
• Molecular Surveillance: PCR-based monitoring, particularly using MLST, can track the introduction of new genotypes and identify vaccine-breakdown strains [24, 28].
• Eradication Programs: In some regions (e.g., the Netherlands), mandatory monitoring and culling of positive breeding flocks have successfully reduced MG seroprevalence from 1.6% to 0.0% in breeding stock [28].

7. Conclusion

Mycoplasma gallisepticum and Mycoplasma synoviae remain significant threats to global poultry production. A thorough understanding of their etiology, pathogenesis, and clinical presentation is essential for accurate diagnosis. The integration of serological and molecular diagnostic tools, particularly qPCR and MLST, provides the most reliable basis for disease detection and strain characterization. Antimicrobial therapy must be guided by susceptibility testing to mitigate the growing problem of resistance. Ultimately, effective control depends on the rigorous application of biosecurity, strategic vaccination, and continuous surveillance.

References

[1] Yadav, J., Tomar, P., Singh, Y., et al. (2021). Insights on Mycoplasma gallisepticum and Mycoplasma synoviae infection in poultry: a systematic review. Animal Biotechnology.

[2] Ramadan, N. (2019). Mycoplasma Gallisepticum Overview in Poultry. American Journal of Biomedical Science & Research.

[3] Feberwee, A., Ferguson-Noel, N., Catania, S., et al. (2024). Mycoplasma gallisepticum and Mycoplasma synoviae in commercial poultry: current control strategies and future challenges. Avian Pathology.

[4] Luitel, P., Gandge, R., Majee, S. (2020). Molecular Detection of Mycoplasma synoviae Infection in Poultry. Asian Journal of Research in Animal and Veterinary Sciences.

[5] Galluzzo, P., Migliore, S., Galuppo, L., et al. (2022). First Molecular Survey to Detect Mycoplasma gallisepticum and Mycoplasma synoviae in Poultry Farms in a Strategic Production District of Sicily (South-Italy). Animals.

[6] Shiferaw, J., Shifara, F., Tefera, M., et al. (2022). Seroprevalence and Associated Risk Factors of Mycoplasma gallisepticum Infection in Poultry Farms of Hawasa and Bishoftu, Central Ethiopia. Veterinary Medicine.

[7] Marouf, S., Khalf, M. A., Alorabi, M., et al. (2021). Mycoplasma gallisepticum: a devastating organism for the poultry industry in Egypt. Poultry Science.

[8] Giram, P., Bhutada, P., Prajapati, C., et al. (2022). Percent positivity and phylogenetic analysis of Mycoplasma gallisepticum and Mycoplasma synoviae in commercial poultry from the different States of India. Veterinary World.

[9] Farooq, S. (2021). Biological Characterization of Locally Circulating Mycoplasma gallisepticum in Poultry. Pakistan Veterinary Journal.

[10] Al-baqir, A., Hassanin, O., Al-Rasheed, M., et al. (2023). Mycoplasmosis in Poultry: An Evaluation of Diagnostic Schemes and Molecular Analysis of Egyptian Mycoplasma gallisepticum Strains. Pathogens.

[11] Marouf, S., Moussa, I., Salem, H., et al. (2020). A picture of Mycoplasma gallisepticum and Mycoplasma synoviae in poultry in Egypt: Phenotypic and genotypic characterization. Journal.

[12] Kulappu Arachchige, S. N., Abeykoon, A., Stevenson, M. A., et al. (2025). Assessment of tracheal mucosal thicknesses is a preferable method for evaluation of the immunogenicity of Mycoplasma gallisepticum vaccines in poultry. Vaccine.

[13] Yadav, J., Singh, Y., Jindal, N., et al. (2021). Rapid and specific detection of Mycoplasma gallisepticum and Mycoplasma synoviae infection in poultry using single and duplex PCR assays. Journal of Microbiological Methods.

[14] Jin, X., Huo, J., Yao, Y., et al. (2024). A multi-dimensional validation strategy of pharmacological effects of Radix Isatidis Mixtures against the co-infection of Mycoplasma gallisepticum and Escherichia coli in poultry. Poultry Science.

[15] Liu, H., Pan, S., Wang, C., et al. (2025). Review of respiratory syndromes in poultry: pathogens, prevention, and control measures. Veterinary Research.

[16] Ardiçli, Ö., Serim Kanar, T., Kahya Demirbilek, S., et al. (2023). Co-infection of S1 mutants of 4/91-like Infectious Bronchitis Virus with Mycoplasma gallisepticum in backyard poultry flock with a respiratory problem. Ankara Üniversitesi Veteriner Fakültesi Dergisi.

[17] Hutton, S., Bettridge, J., Christley, R. M., et al. (2016). Detection of infectious bronchitis virus 793B, avian metapneumovirus, Mycoplasma gallisepticum and Mycoplasma synoviae in poultry in Ethiopia. Tropical Animal Health and Production.

[18] Elyazeed, H., Al-Atfeehy, N. M., Abotaleb, R., et al. (2020). Preparation of ELISA and Lateral Flow Kits for rapid Diagnosis of Mycoplasma gallisepticum in Poultry. Scientific Reports.

[19] Amorim, M. M. R., Bandeira, R. P., Clemente, S. M., et al. (2024). Serological and Molecular Diagnosis of Mycoplasma gallisepticum and Mycoplasma synoviae in Poultry Farms. Brazilian Journal of Poultry Science.

[20] Muhammad, J., Rabbani, M., Sheikh, A., et al. (2021). Molecular detection of Mycoplasma gallisepticum in different poultry breeds of Abbottabad and Rawalpindi, Pakistan. Brazilian Journal of Biology.

[21] Yadav, J. P., Batra, K., Singh, Y., et al. (2024). Comparative study on conventional and real-time PCR assays for rapid and specific detection of Mycoplasma gallisepticum infection in poultry. The Microbe.

[22] Hosny, R. A., El Masry, D. M. A., Saad, A. S. A., et al. (2025). Highlight on the synergistic effect of different microemulsion formulations on the virulence determinants of multi-resistant Mycoplasma gallisepticum recovered from poultry. International Microbiology.

[23] Zidi, S., Khadraoui, N., Essid, R., et al. (2026). Spirulina platensis as a novel natural antimicrobial against macrolide-resistant Mycoplasma gallisepticum in poultry. Frontiers in Microbiology.

[24] Forero-Marin, S., Gomez, A. P., Beltran-Leon, M., et al. (2025). A first look into the genomic characterization and fluoroquinolone resistance genotypes of Mycoplasma spp. in Colombian poultry. Poultry Science.

[25] Mazhar, M. W. (2022). Molecular Detection of Mycoplasma Gallisepticum and Mycoplasma Synoviae Infection in Poultry. Biomedical Journal of Scientific & Technical Research.

[26] Kammon, A., Mulatti, P., Lorenzetto, M., et al. (2017). Biosecurity and geospatial analysis of mycoplasma infections in poultry farms at Al-Jabal Al-Gharbi region of Libya. Open Veterinary Journal.

[27] Le Gall-Ladevèze, C., Nouvel, L., Souvestre, M., et al. (2021). Detection of a novel enterotropic Mycoplasma gallisepticum-like in European Starling (Sturnus vulgaris) around poultry farms in France. bioRxiv.

[28] Veen, C. T., Dijkman, R., de Wit, J. J. D., et al. (2020). Decrease of Mycoplasma gallisepticum seroprevalence and introduction of new genotypes in Dutch commercial poultry during the years 2001–2018. Avian Pathology. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[29] Kapetanov, M., Orlić, D., Potkonjak, D., et al. (2010). Mycoplasma in poultry flocks in the year 2009 compared to the year 2000 and significance of the control measures. Journal.

[30] Fujisawa, S., Murata, S., Takehara, M., et al. (2019). Molecular detection and genetic characterization of Mycoplasma gallisepticum, Mycoplama synoviae, and infectious bronchitis virus in poultry in Myanmar. BMC Veterinary Research.

[31] Shoaib, M. (2020). Sero-Prevalence and Associated Risk Factors of Mycoplasma Gallisepticum, Mycoplasma Synoviae and Salmonella Pullorum / Gallinarium in Poultry. Pakistan Veterinary Journal.

[32] Singh, D., Jhandai, P., Gupta, R., et al. (2020). Epidemiological studies on Mycoplasma synoviae infection in poultry in parts of Haryana. Journal.

[33] Thopireddy, N. R., Bollini, S., Nagaram, V. K. (2023). Comparative study of molecular variations in Mycoplasma synoviae field isolates from common respiratory infections of poultry in Andhra Pradesh. Indian Journal of Poultry Science.

[34] Prajapati, A., Subhashree, N., Susan, J., et al. (2018). Prevalence of Mycoplasma gallisepticum and Mycoplasma synovae in Poultry- India Perspective. Journal.

[35] Kadja, M., Sourokou, S., Kouma, A., et al. (2021). Seroprevalence Study of Mycoplasma gallisepticum and Mycoplasma synoviae Infection in Modern Poultry Farms in the Agnibilekrou Region (Ivory Coast). Asian Journal of Poultry Science.